<SEC-DOCUMENT>0001213900-26-042018.txt : 20260409
<SEC-HEADER>0001213900-26-042018.hdr.sgml : 20260409
<ACCEPTANCE-DATETIME>20260409163028
ACCESSION NUMBER:		0001213900-26-042018
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260409
FILED AS OF DATE:		20260409
DATE AS OF CHANGE:		20260409

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InflaRx N.V.
		CENTRAL INDEX KEY:			0001708688
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38283
		FILM NUMBER:		26852011

	BUSINESS ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745
		BUSINESS PHONE:		49 3641 508180

	MAIL ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Fireman B.V.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0285515-6k_inflarx.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>UNITED STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>SECURITIES AND
EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">Washington, D.C.
20549</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>FORM 6-K</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Report of Foreign
Private</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Issuer Pursuant
to Rule</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>13a-16 or 15d-16
of the</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Securities Exchange
Act</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>For the month
of April 2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">Commission File</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">Number: 001-38283</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>InflaRx N.V.</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Winzerlaer Str.
2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>07745 Jena,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Germany</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(+49) 3641508180</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">(Address
of principal executive offices)</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
Form 40-F &thinsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>INCORPORATION
BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">On April 9, 2026,
InflaRx N.V. (the &ldquo;Company&rdquo;) issued a press release titled &ldquo;InflaRx Reports New Mechanistic Data for Izicopan Supporting
its Potential as a Best-in-Class C5aR Inhibitor.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Company today
announced new in vitro findings conducted through a mechanistically informative Ki-based TDI (Ki/Kinact) study that demonstrates izicopan
does not exhibit time-dependent inhibition of CYP3A4, an important indicator for the risk for drug-drug interactions (DDIs) and liver
toxicity. These results further support izicopan&rsquo;s potential as a differentiated, best-in-class oral C5a receptor inhibitor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Using two probe substrates, midazolam
and testosterone, no evidence of CYP3A4 time-dependent inhibition was observed, providing mechanistic confirmation of izicopan&rsquo;s
favorable pharmacological profile. This&nbsp;feature&nbsp;is particularly important, as time-dependent CYP3A4&nbsp;inhibition can result
in DDIs, hepatotoxicity, or reduced metabolism of concomitant medications such as corticosteroids.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This report on
Form 6-K (the &ldquo;Report&rdquo;) shall be deemed to be incorporated by reference into (i) the registration statements on Form S-8
(File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1708688/000095010317011321/dp82802_s-8.htm">333-221656</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1708688/000114036120017017/brhc10013845_s8.htm">333-240185</A>) and (ii) the registration statement on Form F-3 (File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1708688/000114036123032443/ny20009510x1_f3.htm">333-273058</A>) of the Company and to be a
part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed
or furnished.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">A copy of the press
release is attached as Exhibit 99.1 to this Report. Exhibit 99.1 shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>FORWARD-LOOKING STATEMENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">This Report contains forward-looking
statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms
such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;target,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;predict,&rdquo; &ldquo;potential&rdquo; or &ldquo;continue,&rdquo; among others. Forward-looking statements appear in a number
of places throughout this Report and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current
expectations and the risks, uncertainties and other factors described under the headings, &ldquo;Risk factors&rdquo; and &ldquo;Cautionary
statement regarding forward-looking statements,&rdquo; in our periodic filings with the U.S. Securities and Exchange Commission. These
statements speak only as of the date of this Report and involve known and unknown risks, uncertainties and other important factors that
may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information
becomes available in the future, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>




<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>EXHIBIT INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt; width: 9%"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt; width: 90%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="ea028551501ex99-1.htm">Press Release, dated April 9, 2026</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>





<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>INFLARX N.V.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Date: April 9, 2026</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ Niels Riedemann</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 31%"><FONT STYLE="font-size: 10pt">Niels Riedemann</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea028551501ex99-1.htm
<DESCRIPTION>PRESS RELEASE, DATED APRIL 9, 2026
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><IMG SRC="ea028551501ex99-1_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">InflaRx Reports New Mechanistic Data
for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jena, Germany, April 9, 2026 </B>&ndash; InflaRx
N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
new in vitro findings demonstrating that izicopan does not exhibit time-dependent inhibition of CYP3A4, an important indicator for the
risk for drug-drug interactions (DDIs) and liver toxicity. These results further support izicopan&rsquo;s potential as a differentiated,
best-in-class oral C5a receptor (C5aR) inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To build upon previous CYP interaction data for
izicopan, which showed only marginal inhibition of CYP3A4 (IC&#8325;&#8320; = 62 &micro;M) in a time-dependent inhibition (TDI) IC&#8325;&#8320;
shift assay, InflaRx conducted a mechanistically informative Ki-based TDI (Ki/Kinact) study. While TDI shift assays serve as rapid screening
tools to identify potential time-dependent inhibition, Ki/Kinact studies provide a more definitive and quantitative assessment, enabling
a reliable determination of the presence or absence of time-dependent inhibition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Ki-based TDI study confirms that izicopan
does not inhibit CYP3A4 (IC&#8325;&#8320; &gt; 100 &micro;M) and exhibits no time-dependent inhibition up to the highest tested concentration
(100 &micro;M), supporting a low risk of clinically relevant DDIs. Using two probe substrates, midazolam (MDZ) and testosterone (TES),
no evidence of CYP3A4 time-dependent inhibition was observed, providing mechanistic confirmation of izicopan&rsquo;s favorable pharmacological
profile. This feature is particularly important, as time-dependent CYP3A4 inhibition can result in DDIs, hepatotoxicity, or reduced metabolism
of concomitant medications such as corticosteroids.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prof. Renfeng Guo, Chief Scientific Officer
and Founder of InflaRx,</B> commented: &ldquo;These new mechanistic data highlight izicopan&rsquo;s differentiated pharmacological profile,
demonstrating no CYP3A4 time-dependent inhibition even at high concentrations. Combined with its favorable metabolic stability and human
PK/PD profile, izicopan has the potential to minimize drug&ndash;drug interaction and liver toxicity risks, offering significant benefits
for patients across multiple inflammatory diseases.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>About izicopan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Izicopan is an orally administered, small molecule
inhibitor of the C5a receptor C5aR1 that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models and in
human studies. Further, in contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that izicopan does not inhibit the
cytochrome P450 3A4 (CYP3A4) enzyme, which plays an important role in the metabolism of a variety of metabolites and drugs, including
glucocorticoids. Reported results from a first-in-human study demonstrated that izicopan was well tolerated in treated subjects and exhibited
no safety signals of concern in single doses ranging from 3 mg to 240 mg or multiple doses ranging from 30 mg once per day to 90 mg twice
per day for 14 days. Pharmacokinetic / pharmacodynamic data support the best-in-class potential of izicopan, with a &ge;90% blockade of
C5a-induced neutrophil activation achieved over the 14-day dosing period. Topline Phase 2a data further support the safety profile of
izicopan, with no reported safety signals of concern. In patients with hidradenitis suppurativa, over 4 weeks of therapy, izicopan provided
rapid and clinically meaningful reductions in abscesses and nodules (ANs) and draining tunnels (dTs), robust HiSCR responses that continued
to deepen four weeks after the treatment period, and substantial reductions in patient-reported pain scores, overall demonstrating the
potential for biologic-like efficacy. In chronic spontaneous urticaria, InflaRx observed substantial reductions in the 7-day Urticaria
Activity Score (UAS7) broadly across patients and particularly in those with severe disease, as well as improved disease control as measured
by the Urticaria Control Test (UCT7).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ea028551501ex99-1_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>About InflaRx N.V.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">InflaRx (Nasdaq: IFRX) is a biopharmaceutical
company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop
and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful
inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx&rsquo;s lead program is izicopan,
an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics
as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of several
inflammatory diseases, including hidradenitis suppurativa. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class,
anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability
in multiple clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">InflaRx was founded in 2007, and the group has
offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de.
InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Contacts:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>InflaRx N.V.</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>MC Services AG</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jan Medina, CFA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vice President, Head of Investor Relations</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: IR@inflarx.de</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Katja Arnold, Laurie Doyle, Dr. Regina Lutz</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: inflarx@mc-services.eu</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Europe: +49 89-210 2280</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">U.S.: +1-339-832-0752</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking statements.
All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo;
&ldquo;target,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;believe,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential&rdquo;
or &ldquo;continue,&rdquo; among others. Forward-looking statements appear in a number of places throughout this release and may include
statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things,
the success of our future clinical trials for vilobelimab&rsquo;s treatment of other debilitating or life-threatening inflammatory indications,
including acute respiratory distress syndrome, or ARDS; potential strategic transactions or collaborations, including a potential partnership
of izicopan, or vilobelimab for PG; the success of our future clinical trials for izicopan, and whether such clinical results will reflect
results seen in previously conducted pre-clinical studies and clinical trials; the timing, progress and results of pre-clinical studies
and clinical trials of vilobelimab, izicopan and any other of our product candidates and statements regarding the timing of initiation
and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available,
the costs of such trials and our research and development programs generally; our interactions with regulators regarding the results of
clinical trials and potential regulatory approval pathways, including related to our biologics license application submission for GOHIBIC
(vilobelimab), and our ability to obtain and maintain full regulatory approval of vilobelimab or GOHIBIC (vilobelimab) for any indication;
whether the FDA, or any comparable foreign regulatory authority will accept or agree with the number, design, size, conduct or implementation
of our clinical trials, including any proposed primary or secondary endpoints for such trials; our ability to leverage our proprietary
anti-C5a and anti-C5aR technologies to discover and develop therapies to treat complement-mediated immunological and inflammatory diseases;
our ability to protect, maintain and enforce our intellectual property protection for vilobelimab, izicopan and any other product candidates,
and the scope of such protection; our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing
methods and processes and the optimization of our manufacturing methods and processes, and our ability to continue to rely on our existing
third-party manufacturers and our ability to engage additional third-party manufacturers for our planned future clinical trials and for
commercial supply of vilobelimab and for the finished product GOHIBIC (vilobelimab); our estimates of our expenses, ongoing losses, future
revenue, capital requirements and our needs for or ability to obtain additional financing; our ability to defend against liability claims
resulting from the testing of our product candidates in the clinic or, if approved, any commercial sales; if any of our product candidates
obtain regulatory approval, our ability to comply with and satisfy ongoing obligations and continued regulatory overview; our ability
to comply with enacted and future legislation in seeking marketing approval or commercialization; our future growth and ability to compete,
which depends on our retaining key personnel and recruiting additional qualified personnel; and our competitive position and the development
of and projections relating to our competitors in the development of C5a and C5aR inhibitors or our industry; and the risks, uncertainties
and other factors described under the heading &ldquo;Risk Factors&rdquo; in our periodic filings with the SEC. These statements speak
only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause
our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed
or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance
on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes
available in the future, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea028551501ex99-1_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028551501ex99-1_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  S )\# 2(  A$! Q$!_\0
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=\,,<C+'-;RK(HZ, ,C/X@5]/T44V-A1112$?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
